Skip to main content
Oregon.gov Homepage

COVID-19 Healthcare Partner Resources

COVID-19 Vaccine Information by County

 For all Providers

 For Immunization Providers

Reports

Data

OHA COVID-19 Website

FAQs by Topic

COVID-19 News from OHA

Sign up for Coronavirus Updates

Contact Us

Pandemic Resources

Bamlanivimab (Eli Lilly and Company)​

​

On November 9, 2020, the Food and Drug Administration released an Emergency Use Authorization (EUA) for the release of Eli Lilly and Company's monoclonal antibody therapy, Bamlanivimab, for the treatment of test-confirmed COVID-19 positive patients (adults and children aged greater than 12 years of age and >40kg) with mild to moderate disease. The EUA only includes the treatment ​of​​ non-hospitalized COVID-19 patients with high-risk factors including:

  • Age > 65 years
  • Obesity with BMI > 35 and
  • High risk conditions including diabetes, chronic kidney disease, coronary artery disease, hypertension and others

Full eligibility criteria is available here in Fact Sheet for Healthcare Providers.​

Bamlanivimab should be refrigerated and administered by trained personnel as a single dose infusion of 700mg in the first 10 days after symptom onset in confirmed cases only. Additionally, the requirements of the EUA include that it be administered in settings where providers will be able to monitor for severe side effects including anaphylaxis and can activate emergency medical services as necessary.

The considerations for distribution of this drug include:

  • Space: Dedicated space to treat COVID-19 positive patients with appropriate precautions at facilities equipped to provide infusions
  • Refrigeration: required at 2-8 degrees.
  • Supplies: Simple IV supplies. Can be given by gravity or pump.
  • Staff: Nurse, IV tech with support from physician and pharmacist.
  • Scheduling: infusion time is 1-hour, plus an additional 1-hour post-infusion observation period is required.
  • Reporting: required for adverse events
  • Billing/reimbursement: once commercially available, there could be significant costs for purchasing and administration. While the product is available at no cost in this period, the Medicare payment rate for the infusion of the Bamlanivimab product, will be $309.60. Additional details found on the Medicare Antibody Infusion Program Instruction.

Resources

​

Casirivimab and Imdevimab (Regeneron Pharmaceuticals)

​

On November 21, 2020, the Food and Drug Administration released an Emergency Use Authorization (EUA) for the release of Regeneron Pharmaceuticals' monoclonal antibody therapy, Casirivimab and Imdevimab, for the treatment of test-confirmed COVID-19 positive patients (adults and children aged greater than 12 years of age and >40kg) with mild to moderate disease. The EUA only includes the treatment of non-hospitalized COVID-19 patients with high-risk factors including:

  • Age > 65 years
  • Obesity with BMI > 35 and
  • High risk conditions including diabetes, chronic kidney disease, coronary artery disease, hypertension and others

Full eligibility criteria is available here in Fact Sheet for Healthcare Providers

Casirivimab and Imdevimab should be refrigerated and administered by trained personnel. Although they are packaged separately, casirivimab and imdevimab must be administered together after dilution by single intravenous (IV) infusion only The two products are available in single dose vials of 300mg/2.5ml and 1332mg/11.1ml and should be combined before infusion to include about 1200mg of each product administered together, within the first 10 days after symptom onset in confirmed cases only. Additionally, the requirements of the EUA include that it be administered in settings where providers will be able to monitor for severe side effects including anaphylaxis and can activate emergency medical services as necessary.

The considerations for distribution of this drug include:

  • Space: Dedicated space to treat COVID-19 positive patients with appropriate precautions at facilities equipped to provide infusions
  • Refrigeration: required at 2-8 degrees.
  • Supplies: Simple IV supplies. Can be given by gravity or pump.
  • Staff: Nurse, IV tech with support from physician and pharmacist.
  • Scheduling: infusion time is 1-hour, plus an additional 1-hour post-infusion observation period is required.
  • Reporting: required for adverse events
  • Billing/reimbursement: CMS is providing up to the minute instructions on coding and billing for the infusion of these products. Updated guidance can be found on the CMS website and provided additionally as a link below.

Resources

Oregon Resources

​

Federal Resources

Veklury® (remdesivir)

Resources

​

Playbooks describe the joint collaborative agreement between the Oregon Health Authority, COVID-19 Response and Recovery Unit and other state agencies with the intended goal of stabilizing the spread of a COVID-19 outbreak in a facility or work place. The Playbooks describe the roles and responsibilities of each agency and program as stabilization efforts are coordinated.

Responding to Outbreaks in Agriculture and Farm Operations

The purpose of this plan is to establish the coordination and response efforts of the Oregon Occupational Safety and Health Administration (Oregon OSHA), Oregon Department of Agriculture (ODA), and the Oregon Health Authority (OHA) when one or more cases of COVID19 are identified at a farming operation.

Responding to Outbreaks in a Child Welfare Setting

The document below establishes the coordination and response efforts of the Department of Human Services (ODHS) and Oregon Health Authority (OHA) when one or more positive COVID-19 cases is reported in a facility.

Responding to Outbreaks in Developmental Disability Residential Settings

The document below establishes the coordination and response efforts of the Department of Human Services Office of Developmental Disabilities Services (ODDS) and Oregon Health Authority (OHA) when three or more cases of COVID-19 are associated with a developmental disability residential setting, otherwise known as a facility.

Responding to Outbreaks in Emergency Child Care Setting

The document below establishes the coordination and response efforts of the Early Learning Division (ELD), Office of Child Care (OCC), Oregon Department of Education (ODE), Oregon Department of Human Services (ODHS) and Oregon Health Authority (OHA) when one or more cases of COVID-19 are identified in an Emergency Child Care Setting.

Responding to Outbreaks in Houseless Services Settings

The document below establishes the coordination and response efforts of the Local Public Health Authority (LPHA), COVID Response and Recovery Unit (CRRU), Oregon Department of Human Services (ODHS) and the Oregon Health Authority (OHA) when there is an outbreak in a houseless services setting.

Responding to Outbreaks in Long Term Care Facilities

The document below establishes the coordination and response efforts of the Department of Human Services (DHS), Aging and People with Disabilities (APD) and Oregon Health Authority (OHA) when three (3) or more cases of COVID-19 are associated with a long-term care facility. This coordinated response will help to prevent and slow the spread of COVID-19 and, when it is possible, ensure that these facilities can continue to operate while protecting the public's health. This coordinated agreement allows for proactive strategies to prevent further spread within in a facility.

Joint Response Protocol for COVID-19 Outbreak in a Minor Youth Shelter Setting

This playbook will help establish best practices for proactive, multi-agency coordination and response efforts for COVID-19 outbreaks.

​

COVID-19 Vaccine Provider Enrollment

​Providers wanting to administer COVID-19 vaccine must be fully enrolled through the online enrollment system.

  • To be fully enrolled, the online enrollment system will require providers to register for ALERT IIS and to specifically sign up to receive COVID-19 vaccine.
  • Providers experiencing difficulties or who have questions about the enrollment process may email the Oregon Health Authority's provider enrollment team: Vaccine.ProviderEnroll@dhsoha.state.or.us. Please include your provider type in the subject heading of the email to help us triage our responses.

PDF forms will not be accepted at this time to streamline the process as much as possible. We have provided PDF copies of the enrollment information here to help you prepare to use the online enrollment system.


COVID-19 Vaccine Administration Site and Provider Guidance

This guidance applies to any person operating a vaccine administration site or staffing a site, where an FDA authorized or approved COVID-19 vaccine is being administered, including pharmacies, health clinics, or other non-health care settings.

​

COVID-19 Vaccination Site Non-Discrimination, ADA and Language Access Guidance

Compliance with anti-discrimination laws and the Americans with Disabilities Act (ADA) is the law, and it is particularly critical that operators of vaccination administration sites ensure that there are no barriers to receiving COVID-19 vaccines for communities of color, Deaf people, DeafBlind, people with disabilities, and people who have limited English proficiency (LEP).

More: COVID-19 Vaccine Information for Providers

For Oregon Healthcare Personnel, Partners and Local Public Health

Guidance for Dental Providers

In School Settings

Parent Handouts

Below are handouts that dental providers can provide to parents on coronavirus and oral health, from the National Maternal and Child Oral Resource Center website.

COVID-19 EMS Protocols

Prehospital Guidance for COVID-19

Healthcare Exposure and Work Exclusion

OR-EMSIS Data Collection

Ambulance Reimbursement Policy Changes

Management of COVID-19 in Correctional and Detention Facilities

Administering Naloxone During COVID-19

​

Webinars

​

COVID-19 Vaccine Administration Site and Provider Guidance​

  • COVID-19 Vaccine Administration Site and Provider Guidance 3/24/2021

    • Mask and Face Covering Use in Health Care Offices


    COVID-19 Testing

    Testing Guidance

    NOTE: Clinicians throughout the community can order COVID-19 testing at their discretion through commercial labs WITHOUT approval by public health.

    Testing in K-12 Schools

    To Get Approval for Testing through the Oregon State Public Health Laboratory

    COVID-19 Testing Labs

    Clinical and Infection Control Guidance

    Guidance for Clinics, Hospitals and Long-Term Care Facilities

    CDC Guidance for Clinics and Hospitals

    Admissions and Readmissions

    Entry into Acute Health Care Facilities

    Elective and Non-Urgent Procedures

    Governor's Executive Order 20-22

    Framework for Restarting

    Workgroup on PPE Guidance for Non-Emergency and Elective Procedures

    Resumption and Continued Provision of Non-Emergent and Elective Procedures

    Influenza Testing and COVID-19

    Clients with Suicide Risk

    Traditional Health Workers

    Non-discrimination in Medical Treatment

    Disease Reporting

    ​

    COVID-19 Training: TRAIN Learning Network

    CDC TRAIN provides access to courses developed by the Centers for Disease Control and Prevention (CDC) programs, grantees, and other funded partners. Courses offered by CDC course providers have been approved and verified by CDC.

    Ambulatory practice questions?

    Email cccoperations@ohsu.edu.

    ​

    Behavioral Health Resources for Responders​

    This is a non-exhaustive list of available behavioral health supports. Some of the resources are for individuals actively seeking support for themselves and are also useful for organizational and governmental leaders if signs of stress or burnout are apparent in staff and volunteers. ​

    ​ ​​

    Investigative Guidelines

    ​

    Surge Condition Protocol


    Symptom Monitoring Assessment Templates for Contact Tracing

    For languages not currently supported for automated assessments in ARIAS

    ​​

    Letter Templates

    Case Letter

    Contact Letter

    ADA Guidance

    Isolation and Quarantine Processes

    Risk Communication

    PPE Requests

    ​

    Laboratory-related Terminology and Training

    Ready Schools, Safe Learners LPHA Webinar

    ​

    Guidance for Pharmacies

    Visit the Oregon Board of Pharmacy website for the most recent gui​dance.

    COVID-19 Information Sessions for Oregon Health Care Providers

    ​

    The Healthcare Provider Webinars ended on March 11, 2021. Thanks for your participation.

    View past material (pdf)

    2020

    These documents can be provided upon request in alternate formats for individuals with disabilities or in a language other than English for people with limited English skills. To request this publication in another format or language, email thomas.cogswell@dhsoha.state.or.us, or call 971-304-9642 (voice) or 711 for TTY.

    Watch the recordings (YouTube)

    2020
    ​​​​​​​​​​​​​​​

    This virtual interactive session occurs on the 2nd and 4th Thursday from 12-1:15 pm through June 17. Hosted by the Oregon ECHO Network at OHSU, the session will be staffed by Dr. Hargunani and Dr. Jennifer Vines, Multnomah County Health Officer and other invited content experts. They will provide the latest updates, share COVID-19 clinical cases and answer questions.

    ​Register for the full series

    View past material (pdf)

    2021

    2020

    Watch the recordings

    2021 (Echo360)

    2020 (Vimeo)

    Mask and Face Covering Use in Health Care Offices

    COVID-19 Data and Reports

     OHA COVID-19 Website   COVID-19 Data Dashboards

    Data Reports and Projections


    REALD Data Collection

    Starting October 1, 2020, health care providers subject to Oregon Disease Reporting rules must report REALD information when reporting the following information to the Oregon Health Authority (OHA):

    • Positive or negative COVID-19 cases,
    • COVID-19 hospitalizations or deaths, and
    • MIS-C cases.

    View OHA's fact sheet that describes which providers must start reporting on October 1, 2020 and March 1, 2021.

    Phase 1 providers who cannot start reporting data on October 1, 2020, must submit a compliance plan to OHA by December 31, 2020.

    REALD for Health Care Providers



    Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how

    ×